1492 Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

1492 Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05M	Sell	116,211 -1,945	-2%	-$45.3K	0.9%	37
2026 Q1	$2.78M	Buy	+118,156	New	+$3.02M	1.06%	38
2023 Q3	–	Sell	-222,767	Closed	-$2.12M	–	94
2023 Q2	$2.12M	Sell	222,767 -749	-0.3%	-$8.31K	1.24%	32
2023 Q1	$2.46M	Buy	223,516 +48,970	+28%	+$708K	1.52%	22
2022 Q4	$2.58M	Sell	174,546 -3,774	-2%	-$65.9K	1.67%	20
2022 Q3	$3.41M	Buy	178,320 +361	+0.2%	+$8.18K	2.45%	10
2022 Q2	$3.79M	Buy	177,959 +102,767	+137%	+$2.11M	2.49%	5
2022 Q1	$1.45M	Buy	+75,192	New	+$1.27M	0.77%	47

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

1492 Capital Management's ARQT Position: Q2 2026 in Review

1492 Capital Management reduced its Arcutis Biotherapeutics (ARQT) stake by 1.6% in Q2 2026, selling an estimated $45.3K and leaving 116,211 shares worth $3.05M. The position accounts for 0.9% of the portfolio, ranked #37.

1492 Capital Management first reported a position in ARQT in Q1 2022 and has held it in 8 quarters since. The position peaked at $3.79M in Q2 2022. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

1492 Capital Management held 116,211 shares of Arcutis Biotherapeutics worth $3.05M as of Q2 2026.
1492 Capital Management sold 1,945 Arcutis Biotherapeutics shares in Q2 2026, an estimated $45.3K.
Arcutis Biotherapeutics made up 0.9% of 1492 Capital Management's portfolio in Q2 2026, its #37 holding.
1492 Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 8 quarters since.
1492 Capital Management's Arcutis Biotherapeutics position peaked at $3.79M in Q2 2022.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.